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Background: Low- and middle-income countries (LMICs) account for >90% of deaths and 
illness episodes related to COPD; however, this condition is commonly underdiagnosed in 
these settings. Case-finding instruments for COPD may improve diagnosis and identify 
individuals that need treatment, but few have been validated in resource-limited settings.
Methods: We conducted a population-based cross-sectional study in Uganda to assess the 
diagnostic accuracy of a respiratory symptom, exposure and functional questionnaire in 
combination with peak expiratory flow for COPD diagnosis using post-bronchodilator 
FEV1/FVC z-score below the 5th percentile as the gold standard. We included locally 
relevant exposure questions and statistical learning techniques to identify the most important 
risk factors for COPD. We used 80% of the data to develop the case-finding instrument and 
validated it in the remaining 20%. We evaluated for calibration and discrimination using 
standard approaches. The final score, COLA (COPD in LMICs Assessment), included seven 
questions, age and pre-bronchodilator peak expiratory flow.
Results: We analyzed data from 1,173 participants (average age 47 years, 46.9% male, 4.5% 
with COPD) with acceptable and reproducible spirometry. The seven questions yielded 
a cross-validated area-under-the-curve [AUC] of 0.68 (95% CI 0.61–0.75) with higher scores 
conferring greater odds of COPD. The inclusion of peak expiratory flow and age improved 
prediction in a validation sample (AUC=0.83, 95% CI 0.78–0.88) with a positive predictive 
value of 50% and a negative predictive value of 96%. The final instrument (COLA) included 
seven questions, age and pre-bronchodilator peak expiratory flow.
Conclusion: COLA predicted COPD in urban and rural settings in Uganda has high 
calibration and discrimination, and could serve as a simple, low-cost screening tool in 
resource-limited settings.
Keywords: low- and middle-income countries, COPD, COLA, respiratory symptom
Introduction
Chronic obstructive pulmonary disease (COPD) is a common and preventable 
disease characterized by persistent respiratory symptoms and airflow limitation. 
In 2015, it was estimated that 174 million people worldwide had clinically sig-
nificant COPD, and an estimated 3.2 million individuals died from the disease.1 
Over 90% of morbidity and mortality related to COPD occurs in low- and middle- 
income countries (LMICs), where the primary risk factor for COPD is household 
air pollution secondary to biomass burning for cooking and heating, although the 
prevalence of tobacco smoking is increasing rapidly in these regions.2 COPD is 
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expected to become the third leading cause of death by 
2030 and COPD under diagnosis has been documented to 
be universally high.3
Diagnosis of COPD by post-bronchodilator spirometry 
requires trained technicians to perform the test, and pul-
monary clinicians to interpret the tests who, if available, 
are often localized to a few urban cities in LMIC settings.4 
Additionally, spirometry is resource-intensive to imple-
ment across most existing LMIC health systems. COPD 
case-finding questionnaires have been used in high-income 
settings to identify individuals at risk of COPD in primary 
care clinics for further testing with diagnostic 
spirometry.5–7 These self-reported instruments rely on 
symptoms and risk factors related to COPD and have 
been validated among clinic-based populations with mod-
erately high predictive value. In 2010, Yawn et al devel-
oped and validated a simple five-item Lung Function 
Questionnaire (LFQ) and compared this to COPD diagno-
sis by spirometry (area under the curve [AUC] = 0.720 
with sensitivity (SN) and specificity (SP) of 73.2% and 
58.2%, respectively).7 Martinez et al combined peak 
expiratory flow (PEF) measurements with a case-finding 
instrument and documented improved SN (89.7%), SP 
(93.1%), and AUC for detecting COPD (0.91).5 No instru-
ments to date have been validated in LMIC settings, which 
have a different profile of risk factors and presentation of 
chronic airflow obstruction. Additionally, these question-
naires offer a simple and potentially cost-effective method 
of identifying individuals for definitive testing and/or 
treatment in these settings.
We sought to develop a case-finding questionnaire in 
an LMIC setting, including an assessment of PEF based on 
previously validated questions used in other case-finding 




We conducted a cross-sectional analysis of data collected at 
baseline for the Lung Function in Nakaseke and Kampala 
Study (LiNK) cohort in a rural and an urban sample in 
Uganda between November 2015 and June 2016.8 The 
urban sample was drawn from Kampala, the capital of 
Uganda, with a population of 1.5 million in an estimated 
416,070 households.9 The rural sample was drawn from 
Nakaseke, a health district with 43,167 households and an 
estimated population of 208,500.9,10 A total of 1,502 
participants had acceptable and reproducible spirometry in 
the LiNK cohort. We included respiratory symptoms and 
functional questionnaires among a subset of participants, 
administered at time of spirometry, which are included in 
this analysis (Supplement Data Table 1). As part of this 
ancillary study, we aimed to assess the diagnostic value of 
a questionnaire with multiple domains including respiratory 
symptoms, functional status, and relevant exposures for 
identification of obstruction on spirometry.
Study Design
Twenty-five enumerated areas each were selected from 
Nakaseke and Kampala using probability proportional to 
population size. Inclusion criteria included age ≥35 years 
and less than 95 years, full-time residency in either 
Kampala or Nakaseke, and capacity to consent to the 
study. Exclusion criteria included having active pulmonary 
tuberculosis, a current respiratory infection, or being preg-
nant. The study was approved by the Institutional Review 
Boards of Mulago Hospital and the Uganda National 
Council for Science and Technology in Kampala, Uganda 
and the Johns Hopkins School of Medicine in Baltimore, 
USA.8 All participants provided informed consent, and 
this study was conducted in accordance with the 
Declaration of Helsinki.
Procedures
Anthropometric measurements were taken in triplicate and 
demographic questionnaires including biomass fuel smoke 
exposure, cigarette smoking, HIV status, and history of pul-
monary tuberculosis were administered. Standardized respira-
tory symptom questionnaires modified from the BOLD 
questionnaire were applied in Luganda, the local language 
in the study areas.2 Spirometry was conducted using the 
Easy-On-PC spirometer (ndd, Zurich, Switzerland) according 
to the ATS/ERS guidelines.11 Post-bronchodilator testing 
(400 mcg of inhaled salbutamol via a spacer) was performed 
on all participants with evidence of obstruction defined by the 
NHANES African American reference.12 Participants with 
low-quality spirometry were asked to repeat the test on 
another day for up to three attempts.
Definitions
Household size and secondary education were used as 
proxies for socioeconomic status. We defined exposure to 
biomass fuel smoke as household use of wood or charcoal as 
primary fuel for cooking or heating; daily smoking as self- 
report of smoking one or more cigarettes per day; 
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urbanization as residing in Kampala; underweight as a body 
mass index (BMI) < 18.5 kg/m2 and obesity as a BMI ≥ 
30 kg/m2. We defined COPD as a post-bronchodilator FEV1 
/FVC ratio Z-score ≤ −1.64 standard deviations using the 
NHANES African American reference population and 
bronchodilator reversibility as a post-bronchodilator 
increase in FEV1 of 12% or more from baseline or an 
increase in FVC of 200 mL or more.13 Peak expiratory 
flow measurements were obtained from pre-bronchodilator 
spirometry.
Risk Factors
We previously conducted a comprehensive literature search 
and interviews with patients and providers in Uganda to 
identify 21 risk factors for COPD (Figure 1).3,5–7 
Questions included demographic background (3 questions), 
exposure history (3 questions), respiratory symptoms (11 
questions), medication use (1 question), family history (1 
question) and functional status (2 questions).
Biostatistical Methods
The primary objective was to test the diagnostic accuracy of 
a multi-domain questionnaire that included questions about 
respiratory symptoms, functional status, personal exposures, 
and age in combination with peak expiratory flow to identify 
participants with COPD in a Ugandan community setting. 
We first divided the dataset into a test set consisting of 80% 
of participants selected using a simple random sample, and 
a validation set consisting of the remaining 20%. We then 
conducted a random forest analysis using 1000 bootstrap 
samples and five variables randomly sampled as candidates 
for each tree to identify the five most important respiratory 
symptoms that identify COPD in the training set.14 We 
added smoking and biomass exposure variables a priori to 
ensure generalizability with other LMIC settings. We uti-
lized conditional inference trees and graphically determined 
cutoff values for age and peak expiratory flow most predic-
tive of airflow obstruction on spirometry. The final case- 
finding instrument, COLA (COPD in LMICs Assessment), 
consisted of seven questions, age and peak expiratory flow 
values. We then developed a scoring system whereby parti-
cipants received 1-point for each of the seven respiratory 
symptoms, exposure and functional questions (if present), 
1-point if the participant was ≥55 years of age, 1-point if 
peak expiratory flow was between 250 and 399 L/min, and 
2-points if peak expiratory flow was less than 250 L/min 
(Table 1).
Using the test set, we used bias reduced logistic regres-
sion to determine the odds of having COPD as a function 
of the COLA score.15 Bias reduction was used given the 
low number of individuals with COPD in each score bin. 
To assess calibration of our prediction model, we plotted 
the observed against predicted prevalence of COPD across 
the range of values of the COLA scores.16 We then tested 
our prediction model using k-fold cross-validation on the 
validation set. To assess discrimination, we estimated the 
AUC of the model in the validation set. We used standard 
measures to measure the diagnostic accuracy of our risk 
Figure 1 Odds of COPD by risk factor. Unadjusted odds of COPD by risk factor 
with 95% CI.
Table 1 Derived COLA Score
Symptoms/Functional Score
Have you had whistling/wheezing in chest in last 12 months 1
Have you brought up phlegm from your chest on most days or 
nights of the week during at least 3 months in at least 2 years?
1
Have you ever been woken up from sleep by wheezing? 1
In the past 12 months, have you had to miss work or have 
your daily activities been impeded because of your respiratory 
problems?
1
In the past 12 months, have you been hospitalized because of 
respiratory problems?
1
Do you currently smoke? 1
Do you use biomass fuel daily? 1
Age score
< 55 years 0
≥ 55 years 1
Peak expiratory flow score
≥ 400 L/min 0
250–399 L/min 1
< 250 L/min 2
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score and peak expiratory flow including sensitivity, spe-
cificity, and AUC on the test set using post-bronchodilator 
spirometry values as the gold standard. Analyses were 
conducted in R version 3.6.2 (Dark and Stormy Night) 




Of 1,173 participants who were enrolled with acceptable 
and reproducible spirometry and complete respiratory 
symptom data, the mean (± SD) age was 47.01 ± 10.6 
years and 46.9% were male (59.8% in rural, 40.3% in 
urban). 329 participants were excluded due to incomplete 
data. Self-reported biomass fuel smoke exposure was high 
in both settings, with the rural setting almost exclusively 
using biomass fuels for cooking (99.6%). We summarized 
demographic characteristics of individuals without COPD 
(n=1,120) and with COPD (n=53) in Table 2. Current 
smoking, age ≥ 55 years, taking medications for shortness 
of breath, and history of tuberculosis were associated with 
COPD. A range of respiratory symptoms including cough 
daily/upon waking; first wheezing attack before age 35 
years; hospitalization due to respiratory illness in 
past year; phlegm on most days over three months in the 
past year; missed work activities due to respiratory illness 
in the past year; wheezing in the past year; wheezing 
interfering with physical activity; and, nocturnal awaken-
ing due to wheezing were also associated with COPD 
(Figure 1).
Building a Risk Score for COPD
Our random forest analyses revealed that the most impor-
tant combination of variables for the identification of 
COPD were: nocturnal awakening with wheezing; phlegm 
on most days over three months in the past year; wheezing 
in the past year; hospitalization due to respiratory symp-
toms in the past year; and, missed work or limitation due 
to respiratory illness in the past year. We included the 
additional variables of current biomass exposure and 
daily cigarette smoking to include relevant exposures 
across other LMIC settings (Table 1).2
Performance of PEF alone was evaluated in relation-
ship to obstruction on spirometry in the training set. We 
also graphically compared peak expiratory flow using 50- 
mL increments to determine optimal cutoffs for differen-
tiating cases from controls (Supplement Figure 1). We 
compared this to estimates generated by conditional infer-
ence trees (266 L/min and 330 L/min) to identify optimum 
values (250 L/min and 400 L/min) for inclusion in our 
final model.
Because there were too few participants at the extremes 
of the COLA total scores to derive meaningful operating 
characteristics of the instruments, we grouped COLA total 
scores into five risk scores as follows: 1 (0–1 points), 2 (2 
points), 3 (3 points), 4 (4 points), and 5 (greater than 5 
points). Calibration against airflow obstruction on spiro-
metry demonstrated that prevalence of COPD on the train-
ing set increased with COLA risk score, and that predicted 
values were similar to observed values (Figure 2). A risk 
score of one (n=465) conferred an observed probability of 
COPD of 0.5% and an estimated probability of 0.8%. 
A risk score of five (n=20) resulted in an observed prob-
ability of COPD of 50% and the highest estimated prob-
ability of COPD (52.7%).
Diagnostic Accuracy
Age and seven questions yielded a cross-validated AUC of 
0.74 (95% CI 0.67–0.81), whereas PEF and seven ques-
tions yielded a cross-validated AUC of 0.83 (95% CI 0.-
78–0.89). The COLA score improved overall 
discrimination (0.83, 95% CI 0.78–0.88) when compared 
to the latter scores (Figure 3). The cross-validated AUC 
was similar to the non-cross validated AUC (0.83 vs 0.83), 
suggesting that the logistic model was not over- 
fitted. We additionally conducted analysis to assess the 
validity of a truncated score (six questions, avoiding a 
duplicate question relating to wheeze), which demon-
strated similar operating characteristics (AUC 
0.82). A COLA score ≥ 5 yielded the highest combination 
of sensitivity, specificity and positive predictive value 
(Table 3).
Discussion
We found that seven questions related to respiratory symp-
toms, functional status and exposure history when com-
bined with PEF and age had good discrimination for 
COPD in a LMIC setting. The most predictive domains 
for identifying COPD included age, daily cough and pro-
duction of phlegm. Our data suggest that questionnaires 
combined with PEF measurements are valid instruments 
for identifying individuals with COPD and provide 
a potential simple and low-cost screening tool for case 
finding in resource-limited settings.
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A number of case-finding instruments have been 
validated in high-income settings.5–7 Yawn et al utilized 
data from the third National Health and Nutrition 
Examination Survey to develop a five-item lung func-
tion questionnaire (LFQ) including age, smoking status 
and respiratory symptoms.7 The model with all items 
had an AUC of 0.72 with SN and SP of 73.2% and 
58.2%, respectively. The authors found that partici-
pants above the age of 50 years had the highest odds 
for having COPD (OR = 3.32, 95% CI = 1.87–5.90), 
followed by dyspnea (OR = 1.99, CI = 1.22–3.27) and 
smoking history (OR = 1.81, CI = 1.33–2.88).7 
Participants among the current cohort who stated 
respiratory symptoms (ie wheeze, phlegm and cough) 
Table 2 Baseline Characteristics of 1,173 LiNK Study Participants with Complete Respiratory Symptom Data






Age, in years: Mean ± SD 1173 54.1 (12.2) 46.7 (10.3) <0.01
Sex: Female 622 20 (37.7%) 602 (53.8%) 0.03
Head of house: Yes 855 46 (86.8%) 809 (72.3%) 0.03
Working: Yes 1066 47 (88.7%) 1019(91.1%) 0.72
Marital status, n (%) 1173 0.63
Single 150 7 (13.2%) 141 (12.6%)
Married 742 35 (66%) 706 (63.1%)
Cohabiting 67 2 (3.8%) 64 (5.8%)
Separated/Divorced 93 2 (3.8%) 90 (8.1%)
Widow/Widower 108 7 (13.2%) 101 (9%)
Household characteristics
Household size, median (IQR) 1173 4 (2, 6) 5 (3, 7) 0.32
Has chimney, n (%) 243 17 (32.1%) 226 (20.3%) 0.06
Current Biomass use, n (%) 1140 53 (100%) 1087 (97.1%) 0.40
Cooking location, n (%) 0.07
Outside the house 576 23 (43.4%) 553 (49.4%)
Inside the main living area 102 1 (1.9%) 101 (9%)
In a separate room/hut 494 29 (54.7%) 465 (41.6%)
Fuel source <0.01
Wood 690 44 (83%) 646 (57.7%)
Coal 450 9 (17%) 441 (39.4%)
Other 33 0 (0) 33 (2.9%)
Smoking status
Daily Smoker 97 10 (18.9%) 87 (7.8%) 0.01
Pack-years: Median (IQR) 1173 0 (0, 1.5) 0 (0, 0) <0.01
Pack-years: Mean ± SD 1173 2.1 (4.8) 0.8 (3.6) 0.01
Lung function, median z-score (IQR)
Pre-bronchodilator FEV 1173 −1.95 (−2.30,-1.60,) −0.30 (−0.37,-0.24) <0.01
Pre-bronchodilator FVC 1173 −0.57 (−1.00,-0.15) −0.27 (−0.33,-0.20) 0.07
Pre-bronchodilator FEV/FVC ratio 1173 −3.43 (−3.85,-3.00) −0.10 (−0.15),-0.04 <0.01
Peak Expiratory Flow 1173 290 (258, 322) 432 (426, 439) <0.01
Body mass index, mean (SD) 1173 21.8 (4.7) 24.9 (5) <0.01
History of pulmonary tuberculosis, n (%) 1173 7 (15.2%) 30 (3%) <0.01
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had higher odds of COPD compared to previous studies 
suggesting that respiratory symptoms may have higher 
discriminatory value in low- and middle-income set-
tings. Individuals with COPD in LMICs are largely 
not on maintenance therapy for respiratory symptoms 
and respiratory symptoms may be more pronounced 
between groups. Furthermore some have suggested 
that COPD found among non-smokers may represent 
a distinct endotype, with a different presentation com-
pared to COPD from cigarette exposure.17,18 The LFQ 
was subsequently validated in a clinic based sample 
with a lower AUC (0.65) and specificity (47.8%), 
though with a higher sensitivity (82.6%).19 Among 
a population-based sample of 9,390 participants, the 
BOLD investigators found among those with moder-
ate/severe COPD, use of questionnaire data alone per-
mitted high sensitivity (97%) but required confirmatory 
spirometry in 80% of participants.20 The COLA score 
demonstrated a higher AUC than studies in 
high-income settings, which is a result of the higher 
discriminatory value of respiratory symptoms in differ-
entiating individuals with COPD in the LMIC cohort.
Martinez et al used random forest analysis to identify 
five items (CAPTURE) with the highest operating charac-
teristics and combined this with PEF.5 Notably, the 
CAPTURE questionnaire did not include age or smoking 
status in the final candidate selection. While the 
CAPTURE questionnaire was comparable to the 5-item 
LFQ in its ability to differentiate people with COPD 
from those without COPD (AUC 0.71 vs 0.795), the addi-
tion of PEF to this questionnaire improved discrimination 
for COPD (SN 89.7%, SP 78.1%, AUC 0.906). Both the 
LFQ and CAPTURE questionnaires were validated against 
a primary care, clinic-based sample in a high-income 
country (HIC) setting. COPD surveys administered in 
HIC primary care settings are neither feasible nor appro-
priate in many LMIC settings, where access to primary 
care is limited for the general population.4,21 Our popula-
tion-based sample reduces bias, as it is validated in both 
urban and rural community settings where the majority of 
COPD occurs, and incorporates biomass exposure which is 
a leading risk factor for COPD globally.2
Although there has been conflicting data to support 
application of case-finding instruments in high-income 
settings, few studies to date have assessed the applica-
tion of these tools in low- and middle-income 
settings.22,23 Jithoo et al found PEF as a simple and 
cost effective screening tool for COPD in the BOLD 
cohort.20 COPD diagnosis and treatment is limited by 
a lack of trained health care providers and spirometry.4,24 
Figure 3 Risk factors for COPD and diagnostic accuracy of demographic and respiratory questionnaires alone, peak expiratory flow (PEF) alone and combined 
questionnaires with PEF. Odds of COPD (left panel) stratified by age and symptom score, PEF and combined age, symptoms/exposure score and PEF with 95% CI. Area 
under the curve (AUC) for COPD (right panel) stratified by age and symptom score, PEF and combined age, symptoms score and PEF with 95% CI.
Figure 2 Calibration of generated model on test set. Log odds of COPD compared 
to 5-point respiratory symptom and exposure selection, age and PEF from random 
forest analysis with best-fit line.
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In the rural district where the study was conducted, there 
was no spirometry available for clinical use at time of 
sampling. As a result, task shifting has been proposed as 
an effective method for improving diagnosis and treat-
ment of chronic respiratory disease in these settings.25 
Case-finding instruments provide simple, low-cost and 
valid tools which can be implemented by local health 
care professionals and community health workers to 
identify individuals with likely COPD and refer to speci-
alty clinics for additional testing and management.24
This study has several strengths. First, we conducted this 
study in a population-based, cross-sectional sample. Few 
patients with respiratory diseases are treated in clinical settings 
in low- and middle-income countries. Second, we assessed the 
efficacy of case finding in urban and rural settings among 
populations with different socioeconomic and exposure his-
tories. Our study also has potential limitations. A major limita-
tion of case-finding instruments, particularly in low- and 
middle-income settings, pertains to the overlap between 
COPD and asthma.26 Many of the questions identified as 
having the greatest odds of identifying COPD, are related to 
asthma. The distinction between asthma and COPD is complex 
and a pragmatic approach may be the ability to define “fixed 
airflow obstruction” through case-finding instruments. As 
such, the diagnostic power of the present instrument is limited 
(Table 3). Further evaluation and spirometry beyond the 
COLA would be required for the decision of initiating treat-
ment. Additionally PEF is largely effort dependent. Use of PEF 
from spirometry data may not be fully extrapolated to clinical 
situations using standard PEF, particularly in the setting of 
bronchodilator response.27 We needed to exclude 329 partici-
pants because of incomplete data, and the overall sample size is 
limited. Additionally, while daily exposure to cigarette expo-
sure was predictive of COPD in high-income settings, we 
found exposure assessments did not have as high discrimina-
tion for COPD as symptoms and peak expiratory flow. 
Cigarette exposure in low- and middle-income settings, while 
increasing, remains low and total pack-years may be difficult to 
assess in rural settings of Uganda where tobacco exposure in 
rural areas may reflect smoking of local tobacco crops as 
opposed to purchased cigarettes.28 Assessment of biomass 
exposure to discriminate COPD was limited due to the ubiqui-
tous use of biomass (wood or charcoal) for cooking in the study 
area. For the purposes of feasibility of administration, peak 
expiratory flow measurements were not standardized to height 
and gender. Lastly, this COPD case-finding instrument will 
require external independent validation with data pertaining to 
exacerbation history and COPD disease severity. Further stu-
dies across LMIC settings will be required and are in progress 
to assess the predictive value of these exposure assessments for 
COPD case finding.24
Conclusions
We developed a seven-item questionnaire, which when com-
bined with age and peak expiratory flow measurements, has 
high discrimination for COPD in a population-based setting. 
Whereas respiratory symptom questionnaires were moder-
ately efficacious in predicting airflow obstruction on spiro-
metry, in our study setting, the presence of common 
respiratory symptoms was highly predictive of COPD. 
Given the high burden of undiagnosed, symptomatic COPD 
in LMICs, case-finding instruments may provide a valuable 
tool in bridging the treatment gap.3 Future studies testing the 
validity of the COLA score across a range of low- and 
middle-income settings, as well as assessing acceptability 
and feasibility among lay health workers, are needed to assess 
effectiveness of case-finding as a public health intervention.29
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≥ 3
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≥ 5
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